1. Home
  2. WAT vs ARCC Comparison

WAT vs ARCC Comparison

Compare WAT & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WAT
  • ARCC
  • Stock Information
  • Founded
  • WAT 1958
  • ARCC 2004
  • Country
  • WAT United States
  • ARCC United States
  • Employees
  • WAT N/A
  • ARCC N/A
  • Industry
  • WAT Biotechnology: Laboratory Analytical Instruments
  • ARCC Finance/Investors Services
  • Sector
  • WAT Industrials
  • ARCC Finance
  • Exchange
  • WAT Nasdaq
  • ARCC Nasdaq
  • Market Cap
  • WAT 17.4B
  • ARCC 15.8B
  • IPO Year
  • WAT 1995
  • ARCC 2004
  • Fundamental
  • Price
  • WAT $382.16
  • ARCC $20.23
  • Analyst Decision
  • WAT Buy
  • ARCC Buy
  • Analyst Count
  • WAT 13
  • ARCC 11
  • Target Price
  • WAT $379.00
  • ARCC $22.50
  • AVG Volume (30 Days)
  • WAT 652.9K
  • ARCC 4.3M
  • Earning Date
  • WAT 11-04-2025
  • ARCC 10-28-2025
  • Dividend Yield
  • WAT N/A
  • ARCC 9.50%
  • EPS Growth
  • WAT 3.82
  • ARCC N/A
  • EPS
  • WAT 10.88
  • ARCC 1.99
  • Revenue
  • WAT $3,105,638,000.00
  • ARCC $3,018,000,000.00
  • Revenue This Year
  • WAT $7.12
  • ARCC $3.68
  • Revenue Next Year
  • WAT $6.22
  • ARCC $5.10
  • P/E Ratio
  • WAT $34.88
  • ARCC $10.14
  • Revenue Growth
  • WAT 6.90
  • ARCC 2.72
  • 52 Week Low
  • WAT $275.05
  • ARCC $18.26
  • 52 Week High
  • WAT $423.56
  • ARCC $23.84
  • Technical
  • Relative Strength Index (RSI)
  • WAT 69.65
  • ARCC 49.13
  • Support Level
  • WAT $340.09
  • ARCC $19.85
  • Resistance Level
  • WAT $391.79
  • ARCC $20.53
  • Average True Range (ATR)
  • WAT 10.91
  • ARCC 0.37
  • MACD
  • WAT 1.20
  • ARCC 0.04
  • Stochastic Oscillator
  • WAT 80.12
  • ARCC 39.33

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

Share on Social Networks: